Viibryd

Viibryd is a brand name of vilazodone, approved by the FDA in the following formulation(s):

VIIBRYD (vilazodone hydrochloride - tablet; oral)

• 
  Manufacturer: FOREST LABS INC
  
  Approval date: January 21, 2011
  
  Strength(s): 10MG, 20MG, 40MG ^[RLD]

Has a generic version of Viibryd been approved?

No. There is currently no therapeutically equivalent version of Viibryd available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viibryd. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Piperidines and piperazines
  Patent 5,532,241
  Issued: July 2, 1996
  Inventor(s): Bottcher; Henning & Seyfried; Christoph & Bartoszyk; Gerd & Greiner; Hartmut
  Assignee(s): Merck Patent Gesellschaft mit beschrankter Haftung
  Piperidine and piperazine derivatives of the formula I ##STR1## wherein Ind is an indol-3-yl radical which is unsubstituted or mono- or polysubstituted by OH, OA, CN, Hal, COR.sup.2 or CH.sub.2 R.sup.2, R.sup.1 is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which is unsubstituted or monosubstituted by CN, CH.sub.2 OH, CH.sub.2 OA or COR.sup.2, Q is C.sub.m H.sub.2m, N or CR.sup.3, A is alkyl having 1-6 C atoms, Hal is F, C1, Br or I, R.sup.2 is OH, OA, NH.sub.2, NHA or NA.sub.2, R.sup.3 is H, OH or OA and m is 2, 3 or 4, and their physiologically acceptable salts, are active on the central nervous system.
  
  Patent expiration dates:
  
  
  • September 29, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
  Patent 7,834,020
  Issued: November 16, 2010
  Inventor(s): Bathe; Andreas & Helfert; Bernd & Neuenfeld; Steffen & Kniel; Heike & Bartels; Matthias & Rudolph; Susanne & Böttcher; Henning
  Assignee(s): Merck Patent Gesellschaft
  The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
  
  Patent expiration dates:
  
  
  • June 5, 2022
    
    ✓ 
    Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 21, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Viibryd Consumer Information (Drugs.com)
• Viibryd Consumer Information (Wolters Kluwer)
• Viibryd Consumer Information (Cerner Multum)
• Viibryd Advanced Consumer Information (Micromedex)
• Vilazodone Consumer Information (Wolters Kluwer)
• Vilazodone Consumer Information (Cerner Multum)
• Vilazodone Advanced Consumer Information (Micromedex)